Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Laggard

Bristol-Myers Squibb Company (BMY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.2%. By the end of trading, Bristol-Myers Squibb Company fell 44 cents (-1.4%) to $32.10 on average volume. Throughout the day, 13.1 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.8 million shares. The stock ranged in price between $32-$32.54 after having opened the day at $32.54 as compared to the previous trading day's close of $32.54. Other companies within the Drugs industry that declined today were: pSivida (PSDV), down 18.7%, Biosante Pharmaceuticals (BPAX), down 16%, Spectrum Pharmaceuticals (SPPI), down 14.3%, and Alimera (ALIM), down 14.1%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $54.72 billion and is part of the health care sector. The company has a P/E ratio of 15.7, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 7.5% year to date as of the close of trading on Tuesday. Currently there are seven analysts that rate Bristol-Myers Squibb Company a buy, two analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

• You can view the full Bristol-Myers Squibb Ratings Report.

On the positive front, Savient Pharmaceuticals (SVNT), up 24.1%, Rosetta Genomics (ROSG), up 9.4%, Targacept (TRGT), up 8.1%, and XenoPort (XNPT), up 8.1%, were all gainers within the drugs industry with Onyx Pharmaceuticals (ONXX) being today's featured drugs industry leader.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Bristol-Myers Squibb Company click any of the following:

• Bristol-Myers Squibb Company Stock Price

• Bristol-Myers Squibb Company Analyst Ratings

• Bristol-Myers Squibb Company Key Stats & Profile

• Bristol-Myers Squibb Company Earnings

• Bristol-Myers Squibb Company Ratio Comparison

• Bristol-Myers Squibb Company Growth Rates

• Bristol-Myers Squibb Company Balance Sheet

• Bristol-Myers Squibb Company Cash Flow

• Bristol-Myers Squibb Company Income Statement